Caption Management, LLC Viking Therapeutics, Inc. Call Options Transaction History

Caption Management, LLC

9 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	BUY	$49.84 - $70.47 $917,056 - $1.3 Million	18,400 Added 7.67%	258,400 $16.4 Million
Q2 2024 Aug 14, 2024	SELL	$47.39 - $80.2 $9.19 Million - $15.6 Million	-194,000 Reduced 44.7%	240,000 $12.7 Million
Q1 2024 May 15, 2024	BUY	$17.4 - $94.5 $5.64 Million - $30.6 Million	324,000 Added 294.55%	434,000 $35.6 Million
Q4 2023 Feb 14, 2024	BUY	$9.24 - $19.64 $739,200 - $1.57 Million	80,000 Added 266.67%	110,000 $2.05 Million
Q3 2023 Nov 14, 2023	SELL	$10.92 - $16.0 $764,400 - $1.12 Million	-70,000 Reduced 70.0%	30,000 $332,000
Q1 2023 May 15, 2023	BUY	$8.08 - $17.33 $808,000 - $1.73 Million	100,000 New	100,000 $1.66 Million
Q1 2021 May 17, 2021	SELL	$5.74 - $9.67 $287,000 - $483,500	-50,000 Closed	0 $0
Q4 2019 Feb 13, 2020	SELL	$6.38 - $8.73 $1.12 Million - $1.53 Million	-175,000 Reduced 77.78%	50,000 $402,000
Q3 2019 Nov 14, 2019	BUY	$6.55 - $8.6 $1.47 Million - $1.94 Million	225,000 New	225,000 $1.55 Million

473

65.6M

5.72M

3.39M

Ticker VKTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 76,688,496
Market Cap $3.25B
Description
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trial...

Get notified when there are updates to the investment portfolio of Caption Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Caption Management, LLC with notifications on news.